Back to Dashboard

M22-003

Lymphoma•NCT06191744•Last updated: 2/17/2026
Recruiting

Study Design

Study Drug

Epcoritamab+ R2

Mechanism of Action

CD20+CD3 bispecific Ab

Sponsor

Unknown

Design

III

Control Arm

Arm B: G-CHOP/ R-CHOP/ BR Arm C: R2

Criteria

Inclusion Criteria

newly diagnosed + stage, III or IV disease, or stage II with bulky disease

Age: Phase: III

Exclusion Criteria

Enrollment

Progress4 / 5

Contact Information

Principal Investigator

Unknown

Study Nurse

鄭采涵

Contact Tel

3974